This site is intended for U.S. health care professionals.
Welcome to the pfizer inflammation & immunology pipeline
select a hexagon to explore trials by therapeutic area
Select a hexagon to learn more
DISEASE
STATE
DERMATOLOGY1,a
PHASE 1
PHASE 2
INHIBITOR
MORE INFO COMING SOON
PHASE 3
INHIBITOR
RECRUITING
INHIBITOR
RECRUITING
DISCOVER OUR PIPELINE COMPOUNDS
Explore the compounds currently under
investigation
KEY DERMATOLOGY COMPOUNDS 1,a
Crisaborole
Inhibitor
Dermatology disease states under investigation:6,7
Atopic dermatitis and stasis dermatitis
Abrocitinib (PF-04965842)
Inhibitor
Dermatology disease states under investigation:8,9
Atopic dermatitis
ONGOING CLINICAL TRIALS
Investigate the latest therapies with
ongoing clinical trials
SEE THE LATEST DEVELOPMENTS IN OUR PHASE 3 TRIALS
Crisaborole is a topical PDE4 inhibitor under
investigation for once daily
use in atopic dermatitis
LEARN MORE ABOUT OUR OTHER ONGOING TRIALS
Brepocitinib is an investigational topical
TYK2/JAK1 inhibitor for plaque
psoriasis
TEC
Inhibitor
A LOOK AT AN ORAL
JAK3/TEC INHIBITOR (ritlecitinib)
Ritlecitinib (PF-06651600) is an investigational small molecule with
FDA
Breakthrough Therapy designation for alopecia areata.1-3
JAKs are enzymes responsible for transducing signals to initiate downstream cascades, resulting in
upregulated genes such as those associated with the expression of several inflammatory
molecules.4
TEC family of non-receptor tyrosine kinases are enzymes that regulate immune cells and can impact cytokine
production and inflammation.5,6
Based on the pathophysiology of alopecia areata, Crohn’s disease, rheumatoid arthritis, ulcerative colitis,
and vitiligo, JAK3 and TEC family of non-receptor tyrosine kinases may be therapeutic targets in each of
these conditions.3,5-15
Ritlecitinib is a JAK3/TEC inhibitor under investigation in subjects with alopecia areata, Crohn’s disease,
rheumatoid arthritis, ulcerative colitis, or vitiligo.1
JAK1
Inhibitor
A LOOK AT AN ORAL/TOPICAL
TYK2/JAK1 INHIBITOR (brepocitinib)
Brepocitinib (PF-06700841) is an investigational small molecule TYK2/JAK1
inhibitor
under investigation in multiple conditions.1
Alopecia areata, atopic dermatitis, Crohn's disease, hidradenitis suppurativa, lupus, plaque psoriasis,
psoriatic arthritis, ulcerative colitis, and vitiligo are complicated diseases; however, there may be an
opportunity to target the JAK pathway in each of these conditions.2-11
TYK2/JAK1 are enzymes responsible for transducing signals to initiate downstream cascades, resulting in
upregulated genes such as those associated with the expression of several inflammatory
molecules.2
Brepocitinib is a TYK2/JAK1 inhibitor under investigation in subjects with alopecia areata, atopic
dermatitis, Crohn's disease, hidradenitis suppurativa, lupus, plaque psoriasis, psoriatic arthritis,
ulcerative colitis, or vitiligo.1
Inhibitor
A LOOK AT AN ORAL
TYK2 INHIBITOR (PF-06826647)
PF-06826647 is under investigation in
hidradenitis suppurativa, plaque
psoriasis, and ulcerative colitis.1
Hidradenitis suppurativa, plaque psoriasis, and ulcerative colitis are complicated diseases; however, there
may be an opportunity to target the TYK2, a member of the JAK family, in these
conditions.2-5
TYK2 is an enzyme responsible for transducing signals to initiate downstream cascades, resulting in
upregulated genes such as those associated with the expression of several inflammatory
molecules.6
PF-06826647 is a TYK2 inhibitor under investigation in subjects with hidradenitis suppurativa, plaque
psoriasis, or ulcerative colitis.1
Inhibitor
A LOOK AT AN ORAL
IRAK4 INHIBITOR (PF-06650833)
PF-06650833 is under investigation in hidradenitis suppurativa and
rheumatoid arthritis.1
Activation of Toll-like and interleukin-1 receptors results in expression of proinflammatory cytokines, such
as TNFα and IL-6, that propagate and amplify the intensity of the innate immune response.2,3 When
receptors are activated, they initiate a signaling cascade that recruits neutrophils, monocytes, and
lymphocytes and results in a robust inflammatory response.4
The kinase activity of IRAK4 is a central node in this signaling cascade and may be key in helping to
regulate the intensity of the immune response.5
PF-06650833 is an IRAK4 inhibitor under investigation in subjects with hidradenitis suppurativa or
rheumatoid arthritis.1
Inhibitor
PHASE 3 TRIAL IN
ATOPIC DERMATITIS
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
Inhibitor
PHASE 3 TRIAL IN
ATOPIC DERMATITIS
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
JAK1
Inhibitor
PHASE 2b TRIAL IN
PLAQUE PSORIASIS
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
JAK1
Inhibitor
PHASE 2b TRIAL IN
ATOPIC DERMATITIS
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
Inhibitor
JAK1
Inhibitor
Inhibitor
PHASE 2a TRIAL IN
HIDRADENITIS SUPPURATIVA
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
Inhibitor
PHASE 2 TRIAL IN
PLAQUE PSORIASIS
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
Select a hexagon to learn more
DISEASE
STATE
GASTROENTEROLOGY1,a
PHASE 1
INHIBITOR
COMPLETED
PHASE 2
DGAT2
INHIBITOR
COMPLETED
INHIBITOR
COMPLETED
INHIBITOR
RECRUITING
PHASE 3
DISCOVER OUR PIPELINE COMPOUNDS
Explore the compounds currently under
investigation
KEY GASTROENTEROLOGY COMPOUNDS1,a
ONGOING CLINICAL TRIALS
Investigate the latest therapies with
ongoing clinical trials
Brepocitinib is an investigational oral
TYK2/JAK1 inhibitor and ritlecitinib is an
investigational oral JAK3/TEC inhibitor for
ulcerative colitis
TEC
Inhibitor
A LOOK AT AN ORAL
JAK3/TEC INHIBITOR (ritlecitinib)
Ritlecitinib (PF-06651600) is an investigational small molecule with
FDA
Breakthrough Therapy designation for alopecia areata.1-3
JAKs are enzymes responsible for transducing signals to initiate downstream cascades, resulting in
upregulated genes such as those associated with the expression of several inflammatory
molecules.4
TEC family of non-receptor tyrosine kinases are enzymes that regulate immune cells and can impact cytokine
production and inflammation.5,6
Based on the pathophysiology of alopecia areata, Crohn’s disease, rheumatoid arthritis, ulcerative colitis,
and vitiligo, JAK3 and TEC family of non-receptor tyrosine kinases may be therapeutic targets in each of
these conditions.3,5-15
Ritlecitinib is a JAK3/TEC inhibitor under investigation in subjects with alopecia areata, Crohn’s disease,
rheumatoid arthritis, ulcerative colitis, or vitiligo.1
JAK1
Inhibitor
A LOOK AT AN ORAL/TOPICAL
TYK2/JAK1 INHIBITOR (brepocitinib)
Brepocitinib (PF-06700841) is an investigational small molecule TYK2/JAK1
inhibitor
under investigation in multiple conditions.1
Alopecia areata, atopic dermatitis, Crohn's disease, hidradenitis suppurativa, lupus, plaque psoriasis,
psoriatic arthritis, ulcerative colitis, and vitiligo are complicated diseases; however, there may be an
opportunity to target the JAK pathway in each of these conditions.2-11
TYK2/JAK1 are enzymes responsible for transducing signals to initiate downstream cascades, resulting in
upregulated genes such as those associated with the expression of several inflammatory
molecules.2
Brepocitinib is a TYK2/JAK1 inhibitor under investigation in subjects with alopecia areata, atopic
dermatitis, Crohn's disease, hidradenitis suppurativa, lupus, plaque psoriasis, psoriatic arthritis,
ulcerative colitis, or vitiligo.1
Inhibitor
A LOOK AT AN ORAL
TYK2 INHIBITOR (PF-06826647)
PF-06826647 is under investigation in
hidradenitis suppurativa, plaque
psoriasis, and ulcerative colitis.1
Hidradenitis suppurativa, plaque psoriasis, and ulcerative colitis are complicated diseases; however, there
may be an opportunity to target the TYK2, a member of the JAK family, in these
conditions.2-5
TYK2 is an enzyme responsible for transducing signals to initiate downstream cascades, resulting in
upregulated genes such as those associated with the expression of several inflammatory
molecules.6
PF-06826647 is a TYK2 inhibitor under investigation in subjects with hidradenitis suppurativa, plaque
psoriasis, or ulcerative colitis.1
BLOCKER
A LOOK AT A BIOLOGIC DIRECTED
AGAINST TNFSF15 (PF-06480605)
PF-06480605 is a biologic that inhibits TNFSF15.1
TNFSF15 may play an important role in modulating the innate and adaptive immune response.2,3
Binding of TNFSF15 to its receptor, DR3, costimulates lymphocyte proliferation and production of cytokines, such as IFNy.2,3
Preliminary evidence suggests a potential role for TNFSF15 and DR3 inflammatory bowel disease.4,5 Human genome studies have identified variants in TNFSF15 that may correlate with increased inflammatory bowel disease risk.4 In biopsied tissue, subjects with ulcerative colitis have increased expression of both TNFSF15 and DR3.5
PF-06480605 is under investigation in subjects with ulcerative colitis.1
IMMUNO-
CYTOKINE
A LOOK AT AN
IL-10 IMMUNOCYTOKINE (DEKAVIL)1,a
Dekavil (PF-06687234; F8-IL10) is under investigation in
rheumatoid arthritis and ulcerative colitis.2
Dekavil is an immunocytokine, an antibody fragment fused to an immunoregulatory cytokine, called
IL-10.1,3,4
As a dual-functioning therapy, the antibody portion binds to a spliced variant of fibronectin that is increased at sites of inflammation.
There is abundant expression at accessible sites of tissue remodeling, while being undetectable in most normal human tissues.1
Dekavil is under investigation in subjects with rheumatoid arthritis or ulcerative colitis.2
aPfizer has an exclusive license from Philogen to develop this compound.5
Inhibitor
PHASE 3 TRIAL IN
ATOPIC DERMATITIS
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
Inhibitor
PHASE 3 TRIAL IN
ATOPIC DERMATITIS
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
TEC
Inhibitor
JAK1
Inhibitor
PHASE 2b TRIAL IN
ULCERATIVE COLITIS
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
BLOCKER
PHASE 2b TRIAL IN
ULCERATIVE COLITIS
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
Inhibitor
PHASE 2b TRIAL IN
ULCERATIVE COLITIS
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
TEC
Inhibitor
JAK1
Inhibitor
PHASE 2a TRIAL IN
CROHN'S DISEASE
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
IMMUNO-CYTOKINE
PHASE 2a TRIAL IN
ULCERATIVE COLITIS
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
Select a hexagon to learn more
DISEASE
STATE
RHEUMATOLOGY1,a
PHASE 1
INHIBITOR
RECRUITING
PHASE 2
PHASE 3
JAK3
INHIBITOR
RECRUITING
JAK3d
INHIBITOR
RECRUITING
DISCOVER OUR PIPELINE COMPOUNDS
Explore the compounds currently under
investigation
KEY RHEUMATOLOGY COMPOUNDS1,a
Tofacitinib
JAK3
Inhibitor
Rheumatology disease states under investigation:2,3
Juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis
ONGOING CLINICAL TRIALS
Investigate the latest therapies with
ongoing clinical trials
SEE THE LATEST DEVELOPMENTS IN OUR PHASE 3 TRIALS
Tofacitinib is a JAK1/JAK3 inhibitor under
investigation for systemic juvenile idiopathic arthritis
Tofacitinib is a JAK1/JAK3 inhibitor under
investigation for juvenile idiopathic arthritis
LEARN MORE ABOUT OUR OTHER ONGOING TRIALS
TEC
Inhibitor
A LOOK AT AN ORAL
JAK3/TEC INHIBITOR (ritlecitinib)
Ritlecitinib (PF-06651600) is an investigational small molecule with
FDA
Breakthrough Therapy designation for alopecia areata.1-3
JAKs are enzymes responsible for transducing signals to initiate downstream cascades, resulting in
upregulated genes such as those associated with the expression of several inflammatory
molecules.4
TEC family of non-receptor tyrosine kinases are enzymes that regulate immune cells and can impact cytokine
production and inflammation.5,6
Based on the pathophysiology of alopecia areata, Crohn’s disease, rheumatoid arthritis, ulcerative colitis,
and vitiligo, JAK3 and TEC family of non-receptor tyrosine kinases may be therapeutic targets in each of
these conditions.3,5-15
Ritlecitinib is a JAK3/TEC inhibitor under investigation in subjects with alopecia areata, Crohn’s disease,
rheumatoid arthritis, ulcerative colitis, or vitiligo.1
JAK1
Inhibitor
A LOOK AT AN ORAL/TOPICAL
TYK2/JAK1 INHIBITOR (brepocitinib)
Brepocitinib (PF-06700841) is an investigational small molecule TYK2/JAK1
inhibitor
under investigation in multiple conditions.1
Alopecia areata, atopic dermatitis, Crohn's disease, hidradenitis suppurativa, lupus, plaque psoriasis,
psoriatic arthritis, ulcerative colitis, and vitiligo are complicated diseases; however, there may be an
opportunity to target the JAK pathway in each of these conditions.2-11
TYK2/JAK1 are enzymes responsible for transducing signals to initiate downstream cascades, resulting in
upregulated genes such as those associated with the expression of several inflammatory
molecules.2
Brepocitinib is a TYK2/JAK1 inhibitor under investigation in subjects with alopecia areata, atopic
dermatitis, Crohn's disease, hidradenitis suppurativa, lupus, plaque psoriasis, psoriatic arthritis,
ulcerative colitis, or vitiligo.1
Inhibitor
A LOOK AT AN ORAL
IRAK4 inhibitor (PF-06650833)
PF-06650833 is under investigation in hidradenitis suppurativa and
rheumatoid arthritis.1
Activation of Toll-like and interleukin-1 receptors results in expression of proinflammatory cytokines, such as TNFα and IL-6, that propagate and amplify the intensity of the innate immune response.2,3 When receptors are activated, they initiate a signaling cascade that recruits neutrophils, monocytes, and lymphocytes and results in a robust inflammatory response.4
The kinase activity of IRAK4 is a central node in this signaling cascade and may be key in helping to regulate the intensity of the immune response.5
PF-06650833 is an IRAK4 inhibitor under investigation in subjects with hidradenitis suppurativa or rheumatoid arthritis.1
IMMUNO-
CYTOKINE
A LOOK AT AN
IL-10 IMMUNOCYTOKINE (DEKAVIL)1,a
Dekavil (PF-06687234; F8-IL10) is under investigation in
rheumatoid arthritis and ulcerative colitis.2
Dekavil is an immunocytokine, an antibody fragment fused to an immunoregulatory cytokine, called
IL-10.1,3,4
As a dual-functioning therapy, the antibody portion binds to a spliced variant of fibronectin that is increased at sites of inflammation. There is abundant expression at accessible sites of tissue remodeling, while being undetectable in most normal human tissues.1
Dekavil is under investigation in subjects with rheumatoid arthritis or ulcerative colitis.2
aPfizer has an exclusive license from Philogen to develop this compound.5
JAK3
Inhibitor
PHASE 3 TRIAL IN
SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
JAK3
Inhibitor
PHASE 2/3 TRIAL IN
JUVENILE IDIOPATHIC ARTHRITIS
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
JAK1
Inhibitor
PHASE 2b TRIAL IN LUPUS
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
Inhibitor
PHASE 1 TRIAL IN LUPUS
This study is currently active. To inquire about this trial, please contact ClinicalTrials.gov_Inquiries@pfizer.com.
This is not a complete representation of all Pfizer pipeline compounds.
This information is current as of April 28, 2020.
The clinical trial information is available at www.clinicaltrials.gov.
Dermatology
Over 5 compounds under investigation in multiple dermatology disease statesalopecia areata
VITILIGO
atopic dermatitis
plaque psoriasis
STASIS DERMATITIS
HIDRADENITIS SUPPURATIVA
JAK1b,c
INHIBITOR
TEC
INHIBITOR
JAK1c
INHIBITOR
JAK1f
INHIBITOR
INHIBITOR
JAK1f
INHIBITOR
INHIBITOR
INHIBITOR
INHIBITOR
JAK1c
INHIBITOR
TECd,e
INHIBITOR
INHIBITOR
INHIBITOR
Gastroenterology
Over 4 compounds under investigation in multiple gastroenterology disease statescrohn's disease
ulcerative colitis
NAFLD/NASHi
INHIBITOR
TEC
INHIBITOR
JAK1c
INHIBITOR
IMMUNO-
CYTOKINE
BLOCKER
INHIBITOR
TEC
INHIBITOR
JAK1c
INHIBITOR
DGAT2
INHIBITOR
INHIBITOR
INHIBITOR
Rheumatology
Over 6 compounds under investigation in multiple rheumatology disease statesLupus
PSORIATIC ARTHRITIS
Rheumatoid arthritis
SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS
JUVENILE IDIOPATHIC ARTHRITIS
INHIBITOR
BLOCKER
JAK1c
INHIBITOR
JAK1c
INHIBITOR
IMMUNO-
CYTOKINE
INHIBITOR
TEC
INHIBITOR
JAK3
INHIBITOR
JAK3l
INHIBITOR
